| SB-TEMPUS |
SB-TEMPUS |
92%
|
Under the Data License Agreement, SB Tempus paid the Company ¥ 7.5 billion ($ 47.9 million) in exchange for the license to an initial records batch, which is recorded in deferred revenue and will be … |
| SB-TEMPUS-CORP |
SB-TEMPUS-CORP |
85%
|
development and commercialization of AI Applications; • our ability to maintain and grow our datasets, including in new disease areas and geographies; • any expectation that the growth of our dataset… |
| TEMPUS-COMPASS-LLC |
TEMPUS-COMPASS-LLC |
85%
|
ing period. In addition to TIME, the Company provides other clinical trial services conducting or supporting studies. Tempus Compass LLC, a subsidiary of the Company, is a contract research organizat… |
| ARCC |
Ares Capital Corporation |
72%
|
Reciprocal relationship from ARCC graph: Reciprocal relationship from TEM graph: Reciprocal relationship from ARCC graph: Reciprocal relationship from TEM graph: to stock options was recorded in the … |
| ARCC |
Ares Capital Corporation |
72%
|
to stock options was recorded in the years ended December 31, 2024, 2023 and 2022. Restricted Stock Awards The Company has previously granted restricted stock awards to employees. Compensation expens… |
| FLGT |
Fulgent Genetics, Inc. |
72%
|
Reciprocal relationship from FLGT graph: Reciprocal relationship from TEM graph: Reciprocal relationship from FLGT graph: Reciprocal relationship from TEM graph: Reciprocal relationship from FLGT gra… |
| GH |
Guardant Health, Inc. |
72%
|
who use genomic sequencing services predominantly for the research they are conducting, the clinical trials they are running, or as a companion diagnostic to the extent their therapeutic relies on a … |
| GH |
Guardant Health, Inc. |
72%
|
Reciprocal relationship from GH graph: Reciprocal relationship from TEM graph: Reciprocal relationship from GH graph: Reciprocal relationship from TEM graph: who use genomic sequencing services predo… |
| IQV |
IQVIA Holdings Inc. |
72%
|
who use genomic sequencing services predominantly for the research they are conducting, the clinical trials they are running, or as a companion diagnostic to the extent their therapeutic relies on a … |
| IQV |
IQVIA Holdings Inc. |
72%
|
Reciprocal relationship from IQV graph: Reciprocal relationship from TEM graph: Reciprocal relationship from IQV graph: Reciprocal relationship from TEM graph: who use genomic sequencing services pre… |
| MS-PK |
Morgan Stanley |
72%
|
arrant was automatically cancelled and terminated for no consideration as AstraZeneca declined to extend its financial commitment before December 31, 2024. See Note 15 for further information. On Dec… |
| MS-PK |
Morgan Stanley |
72%
|
Reciprocal relationship from MS-PK graph: Reciprocal relationship from TEM graph: arrant was automatically cancelled and terminated for no consideration as AstraZeneca declined to extend its financia… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
Reciprocal relationship from MYGN graph: Reciprocal relationship from TEM graph: who use genomic sequencing services predominantly for the research they are conducting, the clinical trials they are r… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
who use genomic sequencing services predominantly for the research they are conducting, the clinical trials they are running, or as a companion diagnostic to the extent their therapeutic relies on a … |
| NEO |
NeoGenomics, Inc. |
72%
|
Reciprocal relationship from NEO graph: rofitability. The market for genetic and molecular testing services is highly competitive and, given the opportunities in this market within the laboratory tes… |
| RXRX |
Recursion Pharmaceuticals, Inc. |
72%
|
e us to successfully deliver results over 98% of the time, assuming tissue is received that meets the minimum requirements we have outlined for our assays. Our investments have allowed us to continuo… |
| RXRX |
Recursion Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from RXRX graph: Reciprocal relationship from TEM graph: e us to successfully deliver results over 98% of the time, assuming tissue is received that meets the minimum requirem… |
| AMBRY-GENETICS-CORPORATION |
AMBRY-GENETICS-CORPORATION |
62%
|
development and commercialization of AI Applications; • our ability to maintain and grow our datasets, including in new disease areas and geographies; • any expectation that the growth of our dataset… |
| CO-LLC |
CO-LLC |
62%
|
nt of $4.0 million and $2.0 million in legal fees paid to third parties, and $97.1 million in revolving loans under the Revolving Credit Facility, which is the aggregate amount of $100.0 million, les… |
| DESCRIPTION-OF-BUSINESS-COMPANY-INFORMATION-TEMP |
DESCRIPTION-OF-BUSINESS-COMPANY-INFORMATION-TEMP |
62%
|
2,416 0 — — — — 310,320 — — 310,320 Stock-based compensation expense — — — — — — 22,974 — — 22,974 Foreign currency translation adjustment — — — — — — — — 4,598 4,598 Net loss — — — — — — — ( 68,037 … |
| EKO-DEVICES-INC |
EKO-DEVICES-INC |
62%
|
Inc. and PaigeAI. In cardiology we may compete with companies such as HeartFlow Inc. and Eko Devices, Inc. We expect other competitors to enter this market, including academic medical centers who dev… |
| FOUNDATION-MEDICINE-INC |
FOUNDATION-MEDICINE-INC |
62%
|
iotech and pharmaceutical companies who use genomic sequencing services predominantly for the research they are conducting, the clinical trials they are running, or as a companion diagnostic to the e… |
| GUARDANT-HEALTH-INC |
GUARDANT-HEALTH-INC |
62%
|
ect to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely… |
| HEARTFLOW-INC-ANUMANA-INC |
HEARTFLOW-INC-ANUMANA-INC |
62%
|
cations products include Roche Holdings, Inc., Caris Life Sciences, Guardant Health, Inc., Illumina, Inc., and others, with respect to our TO test, and Myriad Genetics, Inc., Caris Life Sciences, and… |
| KMI |
Kinder Morgan, Inc. |
62%
|
Reciprocal relationship from KMI graph: Reciprocal relationship from TEM graph: Reciprocal relationship from KMI graph: Reciprocal relationship from TEM graph: s acquisition (the "Ambry Acquisition")… |
| KONICA-MINOLTA-INC |
KONICA-MINOLTA-INC |
62%
|
s acquisition (the "Ambry Acquisition") of Ambry Genetics Corporation, a Delaware corporation ("Ambry"), pursuant to a Securities Purchase Agreement (the "Purchase Agreement") entered into on Novembe… |
| PAIGE-AI-INC-AMBRY-GENETICS-CORPORATION |
PAIGE-AI-INC-AMBRY-GENETICS-CORPORATION |
62%
|
including in new disease areas and geographies; • any expectation that the growth of our datasets will improve the quality of our products and services and accelerate their adoption; • our ability to… |
| PATHOS-AI-INC |
PATHOS-AI-INC |
62%
|
of the Delaware Corporation Law, and any future litigation related to this request could materially adversely affect us. Regardless of their merit, any threatened or actual claims or proceedings can … |
| REAL |
The RealReal, Inc. |
62%
|
Reciprocal relationship from REAL graph: Reciprocal relationship from TEM graph: s acquisition (the "Ambry Acquisition") of Ambry Genetics Corporation, a Delaware corporation ("Ambry"), pursuant to a… |
| REALM-IDX-INC |
REALM-IDX-INC |
62%
|
s acquisition (the "Ambry Acquisition") of Ambry Genetics Corporation, a Delaware corporation ("Ambry"), pursuant to a Securities Purchase Agreement (the "Purchase Agreement") entered into on Novembe… |
